Integrity BMS    

Log In

Forgot Your Password?

Not a member? Click here!

Why Dont Cardiologist Cool Patients
Distal Protection Devices Clinical Trials and Regulatory Pathways
Low-Molecular Weight Heparins in ACS: New Insights from SYNERGY and STEEPLE
Low-Molecular Weight Heparins in ACS: New Insights from SYNERGY, STEEPLE and EXTRACT
Pre-Market Device Evaluation: Industry - Europe



AV Anastomosis ROX for Hypertension

Hypertension remains a leading cause of morbidity and mortality worldwide. Despite optimal medical therapy, a significant number of patients continue to have sub-optimal BP control. The ROX CONTROL HTN study has demonstrated the safety and efficacy of central iliac arteriovenous anastomosis as a measure to control BP in such patients. Mean office systolic blood pressure and systolic 24 h ambulatory blood pressure were reduced by 26.9 and 13.5 mmHg respectively using this technique.

For more, click here




IVUS-Guided PCI Reduces Mortality But Increases Cost

The clinical impact of IVUS-guided PCI remains uncertain. In a study of 401,571 PCI, 24,475 were IVUS guided. The study has indicated that as compared to angiography-guided PCI, the former is associated with reduced in-hospital mortality. IVUS-guided PCI was associated with increased cost of care and vascular complications.

For more, click here





Triple Therapy in PCI Patients Requiring Anticoagulation

The optimal duration of antiplatelet therapy in patients undergoing PCI with DES and requiring oral anticoagulation remains uncertain. The ISAR-TRIPLE trial has indicated that in patients receiving aspirin and oral anticoagulants, reducing the duration of clopidogrel therapy from 6 months to 6 weeks does not lead to superior net clinical outcomes.

For more, click here



TITAX-AMI Randomized Trial 5-Years Results
- Petri Tuomainen, MD
Strokes in TAVR Is it a Deal Breaker?
- Samir Kapadia, MD
CoreValve US Pivotal Trial
- John V. Conte, MD
Myocardial infarction with no obstructive coronary atherosclerosis
- Giampaolo Niccoli, MD, PhD
Incidence, Predictors, and Prognostic Impact of Late Bleeding (≥30 days) Complications after Transcatheter Aortic Valve Replacement (TAVR)
- Philippe Généreux, MD
Minimizing Femoral Artery Access Complications during PCI
- Michael S. Lee, MD

Live Case Demonstration from Kusatsu Heart Center
Osamu Hatoh, MD
Treating CTO via Radial?
Richard R. Heuser, MD
Patient Selection for CTO Recanalization: What Are the Appropriate Criteria?
Tarek Helmy, MD
Treating CTOs: Is There Enough Evidence-Based Data or do We Need Further Randomized Clinical Trials?
Gerald S. Werner, MD, PhD
Indication for CTO PCI: Clinical Rationale and Appropriateness
J. Aaron Grantham, MD
 Click here to visit the WEBEX archives

Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry.
M Burke, et al.
JACC 2015; 65:1605-1615
Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent ImplantationThe ISAR-TRIPLE Trial.
K Fiedler, et al.
JACC 2015; 65:1619-1629
Long-Term Prognosis in Patients With Type 1 and 2 Diabetes Mellitus After Coronary Artery Bypass Grafting.
M Holzmann, et al.
JACC 2015; 65:1644-1652
Sudden Cardiac Arrest During Sports Activity in Middle Age.
E Marijon, et al.
Circ 2015; 131:1384-1391
Noninvasive Imaging of Early Venous Thrombosis by 19F Magnetic Resonance Imaging With Targeted Perfluorocarbon Nanoemulsions.
S Temme, et al.
Circ 2015; 131:1405-1414
Regional Variation in the Incidence and Outcomes of In-Hospital Cardiac Arrest in the United States.
D Kolte, et al.
Circ 2015; 131:1415-1425
Therapeutic Hypothermia After Out-of-Hospital Cardiac Arrest in Children.
F Moler, et al.
NEJM 2015 Online
Central Arteriovenous Anastomosis for the Treatment of Patients With Uncontrolled Hypertension (the ROX CONTROL HTN study): A Randomised Controlled Trial.
M Lobo, et al.
The Lancet 2015; 385:1634-1641
Comparison of Different Interdialytic Intervals Among Hemodialysis Patients on Their Echocardiogram-Based Cardiovascular Parameters.
M Obokata, et al.
AHJ 2015; 169:523-530
A Nationwide Survey on Perception, Experience, and Expectations of Hybrid Coronary Revascularization Among Top-Ranked US Hospitals.
R Harskamp, et al.
AHJ 2015;169:557-563
Prevalence and Impact of Pulmonary Hypertension on Patients With Aortic Stenosis Who Underwent Transcatheter Aortic Valve Replacement.
I Barbash, et al.
AJC 2015; 115:1435-1442
Comparison of Inhospital Mortality, Length of Hospitalization, Costs, and Vascular Complications of Percutaneous Coronary Interventions Guided by Ultrasound Versus Angiography.
V Singh, et al.
AJC 2015; 115:1357-1366

Poll Archives
CoreValve US Pivotal Trial - Transcatheter Aortic Valve Replacement or Surgical Aortic Valve Replacement in Patients With Prior Coronary Artery Bypass Grafting
John V. Conte, M.D.
Alexandra Lansky, M.D.
The REGULATE-PCI Randomized Clinical Trial
Roxana Mehran, M.D.
Marc S. Sabatine, M.D., M.P.H.
Promise Trial
Pamela S. Douglas, M.D.
CoreValve US Pivotal Trial - 2-Year Outcomes
Michael J Reardon, M.D., F.A.C.C.
Sanjit Jolly, M.D.
Rajeev K. Pathak, M.D.
(PROMISE) Trial: Economic Outcomes
Daniel B. Mark, M.D., M.P.H.
Drug-Resistant Hypertension in an Asian Population
Byeong-Keuk Kim, M.D.
Reduced Blood Pressure Lowering Effect of Catheter-Based Renal Denervation in Patients with Isolated Systolic Hypertension: Data from Pooled SYMPLICITY HTN Trials
Felix Mahfoud, M.D.
BEST Trial
Seung-Jung Park, M.D., PhD
Outcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S.
Paul Sorajja, M.D.
Clinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients
Susheel Kodali, M.D.
M. Valgimigli, M.D., PhD
C. Michael Gibson, M.S., M.D.
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial
Michael J. Mack, M.D.
Relation Between Frailty and Outcomes After Transcatheter Aortic Valve Replacement
Philip Green, M.D.
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Marc S. Sabatine, M.D., M.P.H.

Complex Patients Today and Tomorrow: Medtronic DES solutions from Resolute Integrity to bioresorbable stents
Prof. Sigmund Silber, MD
First Report on the Pivotal DESolve Nx trial: 6-month Clinical and Multimodality Imaging Results
Alexandre Abizaid, MD, PhD
One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study
Raul Moreno, MD, et al.
Two-year clinical outcomes in the EVOLVE FHU trial
Ian Meredith, MD, PhD
Stephan Windecker, MD, et al.

Outcomes in More Than 7000 Patients With Diabetes After Implantation of the Resolute Zotarolimus-eluting Stent
Rosli Mohd Ali, MD
Safety update and long-term clinical outcomes from all studies in the RESOLUTE Global Clinical Program
Carlo Di Mario, MD
Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial
Stephan Windecker, MD
Angina Status & TLF Creep: Bioabsorbable Stents (BAS) & Drug-Eluting Stents (DES)
Medtronic, Inc.
Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent
Stephan Windecker, MD
Four-year Outcomes from the Randomized Comparison of a Zotarolimus-eluting and an Everolimus-eluting Stent in the RESOLUTE All Comers Trial
Patrick W Serruys MD, PhD
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Prof. Ran Kornowski, MD

Study Begins for Medtronic’s Endurant Evo AAA Stent Graft System

Early Feasibility Study Begins for Gore TAG Thoracic Branch Endoprosthesis to Treat Aortic Arch Aneurysms

Enrollment Begins for Medtronic’s SYMPLICITY AF Study of Pulmonary Vein Isolation Combined With Renal Denervation to Treat Atrial Fibrillation

First US commercial procedures with the Watchman device

Medtronic announces SPYRAL HTN global clinical trial programme for renal denervation

CoreValve receives first TAVR valve-in-valve indication

First Commercial Procedures in the United States Performed With Boston Scientific’s Watchman Device

The Medicines Company’s Cangrelor Approved in Europe

New Indication Allows Brilinta to Be Crushed for Patients With Difficulty Swallowing

Medtronic’s CoreValve TAVR System Approved in Japan

FDA Approves Valve-in-Valve Procedures With CoreValve TAVR System

Medtronic CoreValve® System Receives FDA Approval for Transcatheter Valve-In-Valve Procedures


Infraredx Launches Advanced TVC Imaging System and TVC Muller Extended Bandwidth NIRS-IVUS Catheter

Medtronic Initiates Pivotal Studies of Resolute Onyx(TM) Drug-Eluting Stent in United States

Toshiba’s Infinix 4DCT Receives FDA Clearance with Aquilion PRIME CT Configuration

Boston Scientific Announces Definitive Agreement To Acquire American Medical Systems' Urology Portfolio For Up To $1.65 Billion

Penumbra Launches POD Embolization Anchoring Device at SIR

Boston Scientific to Acquire American Medical Systems’ Urology Portfolio
Angiomyogenesis & Cell Therapy
Carotid Interventions

Home | CRT2015 | CardioTube | Interesting Cases | Trials | Weekly Poll Archive | Newsletter Archive | Login

Copyright © 2015, CRTONLINE - About / Contact Us. All rights reserved. Privacy Policy
Powered by Multiweb